Short answer
Verastem, Inc. (VSTM) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). August 6, 2026 filing references Exhibit 99.1 for Verastem’s results press release.
Verastem, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- August 6, 2026 filing references Exhibit 99.1 for Verastem’s results press release
- Investors should review Exhibit 99.1 for fiscal-year financial results and management commentary
- CEO Daniel W. Paterson signed the report on August 6, 2026
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue reached $40.1M versus $2.1M, driven by $25.1M AVMAPKI FAKZYNJA sales and a $15.0M COPIKTRA milestone
- Commercial traction is emerging, but $72.8M operating expenses produced a $34.7M GAAP net loss
- Oberland royalty financing provides up to $75M, including $50M expected at closing and $25M contingent on $40M quarterly sales
- Pro forma liquidity of $201.4M is expected to fund operations into the second half of 2027, reducing near-term dilution risk
- VS-7375 entered three registration-directed Phase 2 trials, with enrollment targeted for completion by year-end and data expected in October
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Verastem, Inc. 8-K filings
Get the next VSTM 8-K as it lands
Follow VSTM for push alerts, or ask the research agent what this filing means.